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FIBROBLAST GROWTH FACTOR-21 MEDIATES THE EFFECTS OF 
CHRONIC CONSUMPTION OF REFINED SUGARS 
LELAND CHAN 
ABSTRACT 
 Increased sugar consumption is considered to be a contributor to the worldwide 
epidemics of obesity and diabetes and the consequent cardio metabolic risks. These 
include a significant increase for Type II diabetes and associated multiple comorbidities 
such as non-alcoholic fatty liver disease (NAFLD). The accumulation of excess 
triglycerides characterizes NAFL with a prevalence of up to 53% in morbidly obese 
populations. While in itself benign, fatty liver can progress to non-alcoholic 
steatohepatitis (NASH), which is characterized by apoptosis, inflammation and fibrosis in 
10-20% of individuals. Progression to NASH increases the risk of further deterioration to 
cirrhosis and hepatocellular carcinoma (HCC). However, progression is unpredictable in 
any given individual and no risk factors predisposing to progression have been identified. 
Variation in a limited number of genes, such as patatin-like phospholipase (PNPLA3) and 
transmembrane 6 superfamily member 2 (TM6SF2), have been linked to an increased 
susceptibility to NAFLD.  
Recently, fibroblast growth factor 21 (FGF21) was reported to be a potential 
predictor for NAFLD as it significantly increases in patients with obesity and NAFL. 
Multiple lines of evidence indicate that FGF21 plays an important role in liver 
metabolism in mice and humans, playing a key role in carbohydrate and lipid 
metabolism. FGF21 was originally identified as an endocrine member of the fibroblast 
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growth factor family as it can be released into the circulation.  FGF21 was initially 
assigned a purely metabolic role as infusions led to weight loss and increased glucose 
clearance through induced expression of the GLUT1 transporter. However, FGF21 
biology is now understood to be extremely complex, as it is expressed in many 
metabolically active tissues including, liver, white (WAT) and brown adipose tissue 
(BAT), muscle and pancreas. Functions of FGF21 are distinct in all these tissues. In the 
previous studies from our lab, we have seen fructose consumption, but not glucose, leads 
to an increase in serum FGF21 levels both in humans and mice.  
In general, sugar is typically consumed by humans in the form of sucrose or high 
fructose corn syrup (HFCS), both of which consist of nearly equal amounts of the simple 
sugars, glucose and fructose. Although attention has been focused on sucrose and 
fructose in many studies, no direct comparison was found to study fructose, glucose and 
sucrose. The current study aims to expand on the role of FGF21 in mediating the effects 
of chronic consumption of these refined sugars in mice. Wildtype (WT) and FGF21 
knockout (KO) mice were fed with one of these diets for 20 weeks and in general, mice 
eating diets with high refined sugars gained less weight than mice eating chow, although 
calorie consumption was the same. In terms of body composition, sucrose fed FGF21 KO 
mice had less fat mass compared to chow fed animals. Dextrose fed and fructose fed mice 
had comparable fat mass reduction in WT and KO mice. Interestingly, glucose tolerance 
tests (GTT) showed increased glucose sensitivity in dextrose fed WT and KO mice after 
four weeks, however glucose tolerance decayed after 12 weeks on the diet. At 16 weeks 
fructose fed KO mice had significant increased glucose sensitivity compared to controls. 
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Insulin tolerance tests showed similar results between all cohorts and a larger sample size 
would be needed to elicit any differences. Pyruvate tolerance tests (PTT) showed 
significantly increased hepatic gluconeogenesis in fructose fed KO mice compared to 
controls but not in dextrose or sucrose fed mice.  
Energy expenditure was measured by indirect calorimetry. No significance 
changes were observed in dextrose fed mice compared to chow controls in terms of VO2 
or heat production. Both WT and KO dextrose fed mice had a higher RER, consistent 
with utilization of carbohydrates over fat for baseline energy expenditure. Sucrose fed 
mice showed marked increases in VO2 over an averaged 24-hour period and similarly 
fructose fed mice FGF21 KO mice had increased energy expenditure. Significant 
increases in RER were observed in both WT and KO sucrose fed mice controls and a 
similar trend was observed in WT and KO fructose fed mice.  
Overall, we see differential metabolic effects of all the high carbohydrate diets on 
the mice. Chronic consumption of dextrose only affected glucose sensitivity. Whereas 
chronic consumption of sucrose influences glucose and insulin sensitivity and energy 
expenditure suggesting internal metabolic changes while fructose consumption 
additionally showed increased hepatic gluconeogenesis without the marked increase in 
insulin sensitivity. However, detailed tissue analysis is required to determine specific 
physiological and molecular changes between refined sugar cohorts and the role of 
FGF21 in this context. 
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INTRODUCTION 
 
Obesity is a condition of excess of body fat and is one of the leading causes of 
preventable deaths worldwide (Ward et al., 2016). The World Health Organization 
(WHO) estimates that obesity rates have more than tripled in the past four decades and 
approximately two thirds of the U.S. population is considered overweight with half 
considered obese (Ward et al., 2016; “WHO | Obesity,”). The rise in obesity has been 
associated with increased prevalence of its comorbidities, including diabetes, stroke, 
cardiovascular disease, hyperlipidemia, cancers, nonalcoholic fatty liver disease, 
pulmonary disease, and osteoarthritis among others (Upadhyay, Farr, Perakakis, Ghaly, 
& Mantzoros, 2018). The increase in obesity and its comorbidities have contributed to a 
substantial financial burden. At the individual level, this costs an additional $1152 and 
$3613 per year for extra medications for men and women, respectively (Cawley & 
Meyerhoefer, 2012).  
The cause of obesity is multifaceted with environmental, humoral, and genetic 
aspects (Upadhyay et al., 2018). The average American’s caloric intake has increased 
more than 23% since 1970 which is partially responsible for such weight gains. Nearly 
half of the caloric intake comes from carbohydrates and fats while protein, fruits, and 
vegetables encompass smaller shares of the daily diet (Nielsen, Siega-Riz, & Popkin, 
2002). The increased caloric consumption is exacerbated by the general decrease in 
physical activity and thus decrease in energy expenditure (Church et al., 2011). In 
addition to caloric consumption and physical activity, many genes have also been 
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identified as potential contributors to obesity (Upadhyay et al., 2018). One such gene is 
called the fat mass and obesity-associated (FTO) gene, which encodes for an RNA 
demethylase and is associated with the regulation of energy intake. The FTO gene has 
been compared to 40 genetic determinants of obesity and its polymorphisms have been 
shown to be the strongest contributor (Bjørnland, Langaas, Grill, & Mostad, 2017). 
Additionally, the effects of FTO have also been shown to be modified by lifestyle choices 
such as physical activity, artificially sweetened beverage consumption, and smoking 
(Bjørnland et al., 2017).  
Body Mass Index (BMI) is a screening tool to identify overweight or obese 
individuals. It is a ratio of totally weight to height, however because it cannot distinguish 
between fat mass and lean muscle, it cannot be the sole diagnostic tool for the body 
adiposity or health of an individual (Aune et al., 2016). A high BMI is generally an 
indicator for high body fat. Normal BMI’s range from 18.5 to 25. Overweight is 
classified as between 25 and 30 and obesity is classified as having a BMI over 30 (Aune 
et al., 2016; Cui et al., 2014). 
Obesity can lead to a syndrome termed metabolic syndrome (Saklayen, 2018), which is a 
cluster of conditions where patients have at least 3/5 of the following: obesity, 
hypertension, diabetes, hypertriglyceridemia, or hyperlipidemia (Saklayen, 2018). The 
incidence of metabolic syndrome rises in parallel with obesity and is an example of its 
comorbidities (Perumpail et al., 2017). 
Obesity with or without metabolic syndrome is associated with non-alcoholic 
fatty liver disease (NAFLD). NAFLD is a growing epidemic of liver disease in the 
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United States (Calzadilla Bertot & Adams, 2016). NAFLD is the leading chronic liver 
disorder worldwide and has shown an increased incidence from 1.5 to 6.7 per 10,000 
individuals over the last three decades (Said & Ghufran, 2017). In the US, 30-40% of the 
adults  have NAFLD where 20% of those have inflammation as well, or non-alcoholic 
steatohepatitis (Said & Ghufran, 2017). NAFLD is an overarching term that encompasses 
several aspects of lipid deposition in the liver (Benedict & Zhang, 2017). It is considered 
a hepatic manifestation of metabolic syndrome as it is associated with the same risk 
factors: central obesity, type 2 diabetes mellitus, dyslipidemia and insulin resistance 
(Bellentani, 2017). NAFLD and metabolic syndrome are considered strong predictors for 
each other (Han & Lee, 2017). The pathogenic mechanisms leading to NAFL are not 
fully characterized but insulin resistance is known to play a key role in the development 
(Bugianesi, Moscatiello, Ciaravella, & Marchesini, 2010; Guilherme, Virbasius, Puri, & 
Czech, 2008). It begins with simple steatosis and later stages are associated with hepatitis 
and fibrosis, ultimately leading to cirrhosis and in some cases hepatocellular carcinoma. 
A two-hit model was previously proposed to explain progression of NAFL. First, 
multiple factors such as a sedentary lifestyle, high fat diet, obesity, and insulin resistance 
result in hepatic lipid accumulation. The second “hit” in the model is an inflammatory 
event resulting in fibrosis and scarring of the liver (Paschos & Paletas, 2009). However, 
this model fails to explain all metabolic changes occurring within NAFLD. Instead, a 
multiple hit hypothesis explains how dietary habits and environmental and genetic factors 
lead to insulin resistance, obesity with adipocyte proliferation, and changes in the 
intestinal microbiome (Buzzetti, Pinzani, & Tsochatzis, 2016).  
 4 
Hepatic lipid accumulation occurs when triglycerides formed through the 
esterification of glycerol and free fatty acids (FFA). Diet, adipose tissue lipolysis, or 
hepatic de novo lipogenesis are the main sources for FFAs (Buzzetti et al., 2016). Insulin 
resistance at the level of adipose tissue can facilitate this process as a result of insulin’s 
role in the liver. Gruben et al. states that insulin resistance is selective and only involved 
in glucose metabolism pathways and not de novo lipogenesis pathways. Insulin normally 
inhibits gluconeogenesis in the liver and inhibits lipolysis in adipose tissue (Gruben, 
Shiri-Sverdlov, Koonen, & Hofker, 2014; Kersten, 2001). The inability of insulin to 
inhibit hepatic gluconeogenesis leads to compensatory increased insulin secretion from 
the pancreas which potently increases glucose uptake by hepatocytes and stimulates 
ectopic lipogenesis in the liver (Gruben et al., 2014). 
 The increase of FFAs in the liver translates into an increased fatty acid beta-
oxidation and potentially oxidative stress of the liver. This creates a burden on hepatic 
mitochondria that can result in mitochondrial dysfunction and ultimately hepatocyte 
damage, including ballooned hepatocytes, characteristic of non-alcoholic steatohepatitis 
(NASH) (Mota, Banini, Cazanave, & Sanyal, 2016). Ballooned hepatocyte is a special 
form of cellular degeneration characterized by cellular enlargement, loss of cellular 
polarity, abundance of intracellular lipids and oxidized phospholipids, loss of keratin 8/18 
and accumulation of ubiquitinated proteins (Hirsova & Gores, 2015). Mitochondrial 
dysfunction is associated with  30-40% lower respiration rate in NAFL patients which is 
associated with insulin resistance, mitochondrial uncoupling, and leaking activity 
(Koliaki et al., 2015). The mitochondrial swelling leads to the generation of reactive 
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oxygen species which, along with an increased burden on other cellular components, 
triggers mechanisms for further insulin resistance and inflammation (Benedict & Zhang, 
2017).   
 Diagnosis of NAFLD is difficult as it is asymptomatic until liver decompensation 
occurs (Benedict & Zhang, 2017). Incidental discovery can provide an earlier diagnostic, 
especially when evaluations expose insulin resistance, obesity, or metabolic syndrome 
(both risk factors and disease). Once identified, treatment options are scant. NAFLD is 
reversible in stages of steatosis and NASH, but becomes irreversible once cirrhosis sets 
in. Lifestyle modifications are identified as the most important treatment option. 
Pharmacological treatment options include: medications to target hepatic fat 
accumulation, antioxidants and medication for oxidative stress alleviation, antiobesity 
medication, and antifibrotics (Rotman & Sanyal, 2017). However, advancements in the 
understanding of the mechanism behind NAFLD have identified molecular regulators as 
targets for future therapy. Variation in a limited number of genes, such as patatin-like 
phospholipase (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2), have 
been linked to an increased susceptibility to NAFLD (Sookoian et al., 2015). 
Recently, fibroblast growth factor (FGF21) has been shown as a predictive 
biomarker for NAFLD in humans (J. Dushay et al., 2010; Rusli et al., 2016). FGF21 was 
originally identified as an endocrine member of the fibroblast growth factor family, 
which is secreted into the circulation mainly from the liver (Maratos-Flier, 2017, p. 21). 
FGF21 was initially assigned a purely metabolic role as infusions led to weight loss and 
increased glucose clearance through induced expression of the GLUT1 transporter (Ge et 
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al., 2011). However, FGF21 biology is now understood to be extremely complex, as it is 
expressed in many metabolically active tissues including, liver, white (WAT) and brown 
adipose tissue (BAT), muscle and pancreas (Ffolliott Martin Fisher & Maratos-Flier, 
2016, p. 21). The FGF21 receptor requires an obligate co-receptor called Klothoβ (KLB) 
due to FGF21’s low binding affinity to its FGF receptor. Expression of KLB in various 
tissues is a primary determinant of tissue specificity (Fisher & Maratos-Flier, 2016). The 
diverse functions of FGF21 are distinct in all these tissues and are summarized in Table 1 
(Ffolliott Martin Fisher & Maratos-Flier, 2016). 
Tissue Stimulus Transcriptional 
 Elements 
Signal Target 
tissue 
Effect 
Liver Fasting, ketogenic 
diet, MCD diet, 
sucrose, amino 
acid deficiency 
PPARα, 
ChREBP, FXR, 
ATF4 
Endocrine, 
paracrine? 
Liver, 
adipose 
tissue, 
heart, 
brain 
↑FFA oxidation, 
↓inflammation, 
↑uncoupling, 
↓cardiac 
hypertrophy, 
↑glucose 
tolerance, 
↑energy 
expenditure, 
↓fertility 
BAT Cold exposure ATF2 Autocrine, 
paracrine 
BAT ↑Uncoupling 
IWAT Cold exposure ATF2 Autocrine, 
paracrine 
IWAT ↑Uncoupling 
Muscle Myopathy, 
oxidative stress 
ATF4 Endocrine Adipose 
tissues 
↑Uncoupling 
Pancreas Pancreatitis MIST1 Autocrine, 
paracrine, 
endocrine 
Pancreatic 
acinar 
tissues 
↓Inflammation, 
↑islet survival 
Heart Cardiomyopathy MYoD/ATF2 Autocrine, 
endocrine 
Heart ↓Cardiac 
hypertrophy 
↓Oxidative stress 
Table 1. Overview of FGF21 in animal models. Adapted from (Ffolliott Martin Fisher & Maratos-Flier, 2016) 
Circulating FGF21 levels rise with obesity and likely reflect increased hepatic 
lipid accumulation in humans (Chavez et al., 2009; Chen et al., 2008, p. 21; Zhang et al., 
2008). In mice, multiple manipulations including fasting and consumption of a ketogenic 
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diet, protein insufficiency and amino acid deprivation lead to significant increase in 
FGF21 levels, (Badman et al., 2007; Inagaki et al., 2007), (Laeger et al., 2014). When 
mice are fed a lipotoxic methionine-choline deficient diet, hepatic FGF21 expression 
rises dramatically and mice lacking FGF21 develop significantly worse hepatotoxicity as 
assessed by inflammation and fibrosis (Ffolliott M. Fisher et al., 2014; Lees et al., 2014; 
Tanaka et al., 2015). Similar liver pathologies are seen with high fructose diets (Ffolliott 
M. Fisher et al., 2017), dietary ethanol (Desai et al., 2017), acetaminophen overdose (Ye 
et al., 2014) and after partial hepatectomy and CCl4 administration (Huang et al., 2006); 
hepatic expression of FGF21 rises in wild type mice with these stimuli and absence of 
FGF21 leads to significantly worsened pathology while overexpression is protective. 
Taken together these data suggest that FGF21 has important effects to limit hepatic 
toxicity in response to a variety of stimuli. 
Regulation of FGF21 expression and levels may differ between rodents and 
humans; unlike rodents, circulating FGF21 is not induced by either fasting or 
consumption of ketogenic diets in man (Christodoulides, Dyson, Sprecher, Tsintzas, & 
Karpe, 2009). However, acute consumption of fructose or alcohol markedly increases 
serum FGF21 levels, with a time course similar in rodents and humans (Desai et al., 
2017; J. R. Dushay et al., 2015; Ffolliott M. Fisher et al., 2017). These data suggest that 
FGF21 may play a regulatory role in human liver pathologies. 
Recently, Dushay et al showed an increased FGF21 levels in patients  after an oral 
fructose tolerance test (FTT) (J. R. Dushay et al., 2015).  This suggests that FGF21 plays 
an important role in fructose metabolism. In mice, hepatic expression of FGF21 and the 
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carbohydrate response element binding protein (ChREBP) increased by 2-fold and 3-fold 
respectively following a fructose gavage (Ffolliott M. Fisher et al., 2017). In the presence 
of fructose, ChREBP acutely increases circulating FGF21 levels. In the absence of 
FGF21, fructose fed FGF21 KO mice have increased expression of inflammation markers 
and worse hepatic histology (Ffolliott M. Fisher et al., 2017).  
 Although acute FGF21 responses has been well characterized in fructose fed 
rodents and humans, less work has been done to investigate the chronic physiological 
responses of refined sugars (dextrose, sucrose, and fructose) in mice. In the present study, 
we have investigated the metabolic effects of chronic consumption of high dextrose, high 
sucrose and high fructose diets in WT and FGF21 KO mice. In particular, as FGF21 
deletion leads to significant liver pathology we were interested in the possibility that the 
possible metabolic effects of the diets would be different in the absence of FGF21. 
Evaluation of the animals included regular monitoring of body weights, food intake, body 
composition, glycaemia and energy expenditure.  
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SPECIFIC AIMS 
 
 
1. Review the current knowledge of FGF21 physiology 
2. Investigate the physiological effects of chronic consumption of refined sugars in 
murine models of FGF21 deficiency. 
3. Compare the effects of these different refined carbohydrates diets (dextrose, 
sucrose, fructose) in mice 
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METHODS 
 
Animal models 
All experiments were conducted on 8-10 weeks-old female mice with the following 
genotypes: Wildtype C57BL/6J and FGF21-Knockout mice. Mice were originally 
generated at Eli Lilly Research Laboratories (Indianapolis IN) and have been described 
previously (Badman, Koester, Flier, Kharitonenkov, & Maratos-Flier, 2009; 
Kharitonenkov et al., 2005). Founder mice for each colony were backcrossed onto the 
C57BL/6J line at least 10 times before the initiation of these studies and were used with 
their littermate controls. Mice were kept under a 12 h light: 12 h dark cycle and an 
ambient temperature of 22 ± 2 °C. Mice were anesthetized between 9:00 am and 11:30 
am with ketamine/xylazine. Mouse liver, pancreas, brown adipose tissue, inguinal and 
epididymal white adipose tissue, hypothalamus, nucleus accumbens, and serum were 
collected. The brains were removed and 30 µm thick coronal sections were cut on a 
freezing microtome to collect the hypothalamus and nucleus accumbens. All procedures 
were in accordance with National Institutes of Health Guidelines for the Care and Use of 
Animals and approved by the Institutional Animal Care and Use Committee at Beth 
Israel Deaconess Medical Center (Boston MA). 
 
Animal diets 
Mice were provided with ad libitum access to water and food. The mice were fed with the 
respective diets for 20 weeks. One the following diets were provided: standard animal 
facility chow diet (calories provided from 16.9% fat, 26.5% protein, and 56% 
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carbohydrate in the form of starch 29.4%, 0.21% glucose, 2.79% sucrose, and 0.23% 
fructose) (Formulab Diet 5008 – LabDiet, St. Louis, MO), 60% dextrose diet (calories 
provided from 13% fat, 20.2% protein, and 66.8% carbohydrate) (Teklad Custom Diet 
TD.05256 - Envigo, Madison, WI), high sucrose diet (calories provided from 10% fat, 
20% protein, and 70% carbohydrate) (Rodent Diet with 10 kcal% fat D12450J - Research 
Diets, New Brunswick, NJ), or 60% fructose diet (calories provided from 13% fat, 20.2% 
protein, and 66.8% carbohydrate) (Teklad Custom Diet TD.89247 - Envigo, Madison, 
WI).  
Body composition analysis 
Body composition was determined using an EchoMRI 3-in-1 quantitative nuclear 
magnetic resonance (qNMR) system (Echo Medical Systems, Houston, TX). Body fat, 
lean mass, body fluids, and total body water were measured in live conscious mice with 
ad libitum access to one of the following diets: chow, 60% dextrose, 60% sucrose, 60% 
fructose. 
Indirect Calorimetry 
Mice were maintained on a 12:12-hour light-dark cycle and metabolic rate was measured 
by indirect calorimetry using a Comprehensive Lab Animal Monitoring System 
(CLAMS) (Columbus Instruments, Columbus, OH) and have been described previously 
(Singhal et al., 2016). Sample air was passed through an O2 sensor (Columbus 
Instruments) for determination of O2 content. O2 consumption was calculated by 
examining the difference of O2 concentration of air entering the chamber compared with 
air leaving the chamber and heat production on per-animal basis was calculated from the 
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following equation: (3.82 + 1.23 × RER) × VO2, where the respiratory exchange ratio 
(RER) is the volume of CO2 produced/volume of O2 consumed per hour. The sensor was 
calibrated against a standard gas mix containing defined quantities of O2, CO2, and 
nitrogen. X ambulatory rate is defined as the number of X-axis IR beam breaks every 17 
minutes not including repeated interruptions of the same IR beam. Food and water were 
available ad libitum. 24-hour data collection was averaged and binned to create day and 
night depictions of metabolic rate and normalized to effective mass. 
Glucose Tolerance Test (GTT) 
Female WT and FGF21 KO mice were fasted for approximately 16 h overnight prior to 
experiment. Baseline blood glucose were drawn from the tail vein via tail snip before 
intra-peritoneal injection of 2 g/kg glucose. Repeated measures were taken after 10, 20, 
30, 60, 90 and 120 minutes. Blood glucose was measured using a glucometer with 
Ultratouch (Lifescan) glucose strips. 
Insulin Tolerance Test (ITT) 
Female WT and KO mice were fasted for approximately 6 h prior to experiment. 
Baseline blood glucose were drawn from the tail vein via tail snip before intra-peritoneal 
injection of 1 U/kg insulin. Repeated measures were taken after 15, 30, 45 minutes. 
Blood glucose was measured using a glucometer with Ultratouch (Lifescan) glucose 
strips. 
Pyruvate Tolerance Test (PTT) Protocol 
Female WT and KO mice were fasted for approximately 16 h overnight prior to 
experiment. Baseline blood glucose were drawn from the tail vein via tail snip before 
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intra-peritoneal injection of 1g/kg pyruvate. Repeated measures were taken after 15, 30, 
60, and 120 minutes. Blood glucose was measured using a glucometer with Ultratouch 
(Lifescan) glucose strips. 
Data analysis 
GraphPad Prism v5.0 (La Jolla, CA) was utilized to analyze statistical differences. All 
data are presented as mean ± SEM. Time course experiments were analyzed for 
significant differences using a two-way ANOVA with repeated measures followed by 
Bonferonni’s post-hoc test for individual comparisons. Single point measures for four-
way studies were analyzed using a one-way ANOVA followed by Bonferonni’s post-hoc 
test for individual comparisons. Single point measures for two-way studies were analyzed 
using a two-tailed unpaired T-test. Significance is designated by asterisks with *P < 0.05, 
**P < 0.01, ***P < 0.001, or designated by symbols (ampersand, caret, dollar sign) based 
on comparison groups.  
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RESULTS 
 
 
Female WT and FGF21 KO mice were placed on one of four different diets (chow, 60% 
dextrose, high sucrose, and 60% fructose) for 20 weeks. Body weights were measured 
regularly during the entire course of the experiment. The following tests were carried out 
over the duration of the project: a glucose tolerance test (GTT) to compare glucose 
sensitivity, an insulin tolerance test (ITT) to compare insulin sensitivity, a pyruvate 
tolerance test (PTT) to assess hepatic gluconeogenesis, MRI to assess body composition 
and CLAMS to determine energy expenditure. The experimental paradigm is shown in 
Figure 1. All the mice were sacrificed at 20 weeks and tissues were harvested. Gene 
expression in liver and adipose tissue will be analyzed. 
 
Figure 1. Schematic Representation of the Experimental Timeline. Experiments were repeated across all diet 
cohorts unless otherwise specified. 
 
Body weight 
Prior to the exposure to the diets, mice were weight matched. Body weight measurements 
of mice fed on the three refined sugar diets compared to controls are shown in Figures 
2A-2F. WT and KO mice fed with dextrose showed a marginal body weight gain during 
the entire course of experiment (Fig 2B, WT dextrose: 2%; KO dextrose: 4.6) while chow 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Time (Weeks) 
Serum Blood Glucose Assessment 
Serum Blood 
Glucose - Fructose 
GTT-Fructose 
ITT Fructose 
MRI 3 
PTT 
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MRI 1 Food Intake Assessment 
GTT 3 
MRI-Fructose 
GTT 2 ITT 
MRI 2 
CLAMS GTT 1 
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fed mice gained weight overall (Fig 2B, WT chow: 20%; KO chow: 7.9%). The body 
weight pattern on sucrose diet also remained the same as mice gained very little, 
statistically insignificant body weights (Fig 2D, WT sucrose: 8%; KO sucrose: 4%). 
Interestingly, fructose fed mice showed a reduction in body weight from base line at 16 
weeks (Fig 2F, WT fructose, -1.9%; KO fructose -4.8%) prior to gaining a marginal, yet 
statistical insignificant weight at 20 weeks (Fig 2F, WT fructose 8%; KO fructose: 9.6%).  
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Figure 2. Absolute (2A) and percent (2B) body weight change in chow and dextrose cohorts. Data represented as 
Mean ± SEM; n = 7–8 mice/group. Significance was determined with a one-way ANOVA with repeated measures and 
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Bonferroni's post-hoc analysis test for individual comparisons. Significance between WT chow and WT dextrose ^P < 
0.05, ^^^P < 0.001; KO chow vs KO dextrose &P < 0.05. 
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Figure 2. Absolute (2C) and percent (2D) body weight change in chow and sucrose cohorts. Data represented as 
Mean ± SEM; n = 6–8 mice/group. Significance was determined with a one-way ANOVA with repeated measures and 
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Bonferroni's post-hoc analysis test for individual comparisons. Significance between WT chow and WT sucrose ^P < 
0.05, ^^^P < 0.001; KO chow vs KO sucrose &P < 0.05, &&P < 0.01, &&&P < 0.001. 
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Figure 2. Absolute (2E) and percent (2F) body weight change in fructose cohorts. Data represented as Mean ± 
SEM; n = 7 mice/group. Significance was determined with a two-tailed unpaired t test. No significant differences were 
found. 
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Caloric Intake 
Caloric consumption in each group was measured over three days and is presented in 
caloric content (kcals) shown in Figures 3A-3C. Mice on chow and dextrose had a very 
similar calorie intake (Fig 3A). Similarly, mice on chow and sucrose also had comparable 
calorie intake over 3 days (Fig 3B). On the other hand, WT fructose consumed more 
calories (Fig 3C, WT fructose: 12.4 kcal/g) compared to WT chow (Fig 3C, WT chow: 
9.9 kcal/g) and significantly more than KO fructose mice (Fig 3C, KO fructose: 9.13 
kcal/g). 
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Figure 3. Averaged 3 day caloric intake comparison in chow vs dextrose (3A), sucrose (3B), and fructose (3C). 
Data represented as Mean ± SEM; n = 6-8 mice/group. Statistical analysis was carried out with a two-way ANOVA 
with repeated measures and Bonferroni's post-hoc analysis test for individual comparisons.  No significant differences 
were found. 
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Body Composition Analysis 
Body composition analysis was performed to measure the fat mass (Fig 4) and lean mass 
(Fig 5) in all the cohorts 20 weeks of dietary consumption. Chow fed WT and KO mice 
had higher fat mass compared to dextrose fed mice (Fig 4A). At 20 weeks, significant 
differences in chow fed WT mice and sucrose fed WT mice were observed (Fig 4B, WT 
chow: 10.15g; WT sucrose: 6.2g). Additionally, sucrose fed KO mice had significantly 
less fat mass compared to chow fed KO mice (Fig 4B, KO chow: 8g; KO sucrose: 3.87g). 
In fructose cohorts no differences in fat mass was observed in WT and KO mice (Figure 
4C). All the cohorts had comparable lean mass irrespective of the diet or genotype.  
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Figure 4. Body composition comparison in chow vs refined sugar cohorts represented as absolute fat mass. 
Dextrose (4A) and sucrose (4B) cohorts were assessed at 21 weeks. Fructose (4C) cohorts were assessed at 17 weeks 
Data represented as Mean ± SEM; n = 6-8 mice/group. Significance was determined with a one-way ANOVA with 
repeated measures and Bonferroni's post-hoc analysis test for individual comparisons. Significance between WT chow 
and WT sucrose ^P < 0.05; KO chow vs KO sucrose &P < 0.05. 
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Figure 5. Body composition comparison in chow vs refined sugar cohorts represented as absolute lean mass. 
Dextrose (5A) and sucrose (5B) cohorts were assessed at 20 weeks. Fructose (5C) cohorts were assessed at 17 weeks 
Data represented as Mean ± SEM; n = 6-8 mice/group. Statistical analysis was carried out with a one-way ANOVA 
with repeated measures and Bonferroni's post-hoc analysis test for individual comparisons. No significant differences 
were found. 
 
Serum Blood Glucose 
Serum blood glucose levels were assessed at 11 weeks for dextrose (Fig 6A) and sucrose 
(Fig 6B) and at 20 weeks for fructose (Fig 6C). Compared to chow fed mice, WT 
dextrose had significantly higher blood glucose levels (Fig 6A, WT chow: 138.25 mg/dL; 
WT dextrose: 165.286 mg/dL). Dextrose fed KO mice also had a significantly higher 
blood glucose level (Fig 6A, KO chow: 151.286 mg/dL; KO dextrose: 191.125 mg/dL). 
Sucrose fed WT and KO mice had approximately the same blood glucose levels (Fig 6B, 
WT sucrose: 148.286 mg/dL; KO sucrose: 153.333 mg/dL). Additionally, fructose fed 
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WT and KO mice had comparable blood glucose levels at 20 weeks (Fig 6C, WT 
fructose: 164.429 mg/dL; KO fructose: 182.286 mg/dL). 
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Figure 6. Serum blood glucose assessment in refined sugar cohorts. Dextrose (6A) and sucrose (6B) cohorts were 
assessed at 11 weeks. Fructose (6C) cohort was assessed at 20 weeks. Data represented as Mean ± SEM; n = 6-8 
mice/group. Statistical analysis was carried out with a two-tailed unpaired t-test. Significance is designated by 
asterisks with *P < 0.05 
Glucose Tolerance Test 
Figure 7A illustrates an intraperitoneal GTT between WT and KO mice fed either with 
chow or dextrose diet for 4, 12, and 18 weeks respectively. AUC measurements were 
taken to compare glucose sensitivity. No significant differences were observed between 
chow and dextrose fed WT and FGF21 KO mice at 4 weeks. However, at 12 weeks, KO 
mice fed with dextrose had a significantly higher glucose excursion curve than KO chow 
(Fig 7A-2, KO chow: 25,436 mg*min/dL; KO dextrose: 34,496 mg*min/dL). At 18 
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weeks, worse glucose excursion curve was maintained by dextrose fed KO mice (Fig 7A-
3, WT dextrose: 28,719 mg*min/dL; KO dextrose: 33,888 mg*min/dL). 
Figure 7B illustrates an intraperitoneal GTT between WT and KO mice fed either with 
chow or sucrose diet for 4, 12, and 18 weeks respectively. Interestingly, KO chow had a 
significantly higher AUC than KO sucrose (Fig 7B-1, KO chow: 31,775 mg*min//dL; 
KO sucrose: 26,799 mg*min/dL). With time, this difference decreases and at 18 weeks, 
both chow fed and sucrose fed KO mice had comparable AUCs (Fig 7B-3, KO chow: 
29,966 mg*min//dL; KO sucrose: 29,429 mg*min/dL). No statistically significant 
differences in glucose sensitivity were observed between chow fed or sucrose fed WT 
mice at 4, 12, or 18 weeks. 
Figure 7C represents an intraperitoneal GTT between WT and KO mice fed either with 
chow or fructose diet for 16 weeks. At this time, fructose fed KO mice had significantly 
higher AUC values than chow fed KO mice (Fig 7C-1, KO chow: 27,056 mg*min/dL; 
KO fructose: 38,988 mg*min/dL). On the other hand, WT fructose mice had comparable 
AUC values with WT chow mice (Fig 7C-1, WT chow: 32,319 mg*min/dL; WT 
fructose: 33,756 mg*min/dL). 
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Figure 7A. Glucose Tolerance Test of Chow vs Dextrose Diet Cohorts at 4 weeks, 12, weeks, and 18 weeks. AUC 
values as listed in Tables 7A-1, 7A-2, and 7A-3. Data represented as Mean ± SEM; n = 7-8 mice/group. Significance 
was determined with a two-tailed unpaired t-test. Significance is designated by asterisks with *P < 0.05, **P < 0.01. 
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Figure 7B. Glucose Tolerance Test of Chow vs Sucrose Diet Cohorts at 4 weeks, 12, weeks, and 18 weeks. AUC 
values as listed in Tables 7B-1, 7B-2, and 7B-3. Data represented as Mean ± SEM; n = 6-8 mice/group. Significance 
was determined with a two-tailed unpaired t-test. Significance is designated by asterisks with *P < 0.05. 
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 Figure 7C. Glucose Tolerance Test of Chow vs Fructose Diet Cohorts at 16 weeks. AUC values as listed in Table 
7C-1. Data represented as Mean ± SEM; n = 7 mice/group. Significance was determined with a two-tailed unpaired t-
test. Significance is designated by asterisks with **P < 0.01. 
Insulin Tolerance Test 
Figure 8 represents an intraperitoneal ITT between WT and KO mice fed either with 
chow, dextrose, or sucrose diet for 14 weeks or fructose mice for 17 weeks. AUC 
measurements were taken to compare insulin sensitivity. Chow and dextrose fed WT and 
KO mice had comparable AUC values (Fig 8A, Table 8A-1). Interestingly, sucrose fed 
KO mice had a significantly higher AUC value compared to sucrose fed WT mice (Fig 
8B, WT sucrose: 2,940 mg*min/dL; KO sucrose: 3,949 mg*min/dL) while WT chow and 
WT sucrose mice had comparable AUC values. At 17 weeks, no differences in insulin 
sensitivity were observed in chow or fructose fed WT and KO mice.  
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Figure 8. Insulin Tolerance Test of Chow vs Refined Sugars. Dextrose (8A) and sucrose (8B) cohorts were assessed 
at 14 weeks. Fructose (8C) cohort was assessed at 17 weeks. Respective AUC values as listed in Tables 8A-1, 8B-1, 
and 8C-1. Data represented as Mean ± SEM; n = 6-8 mice/group. Statistical analysis was carried out with a two-tailed 
unpaired t-test. Significance between WT sucrose and KO sucrose is designated by asterisks with *P < 0.05. 
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Pyruvate Tolerance Test 
Figure 9 represents an intraperitoneal PTT between WT and KO mice fed either with 
chow, dextrose, sucrose, or fructose diet for 20 weeks. AUC measurements were taken to 
compare hepatic gluconeogenesis function. Dextrose and sucrose fed cohorts did not 
show any difference in either in WT or FGF21 KO mice fed with either diet.  
However, significant difference was observed between chow fed KO mice and fructose 
fed KO mice at 20 weeks (Fig 9C, KO chow: 14,867 mg*min/dL; KO fructose: 23,243 
mg*min/dL) indicating KO mice with more capacity of hepatic gluconeogenesis.  
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Figure 9. Pyruvate Tolerance Test of Chow vs Dextrose (9A), Sucrose (9B), and Fructose (9C) cohorts at 20 
weeks. Respective AUC values as listed in Tables 9A-1, 9B-1, and 9C-1. Data represented as Mean ± SEM; n = 6-8 
mice/group. Statistical analysis was carried out with a two-tailed unpaired t-test. Significance between KO chow vs KO 
fructose is designated by asterisks with *P < 0.05. 
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Indirect Calorimetry 
The metabolic rate was measured in all the mice to assess their energy expenditure. 
Including parameters such as VO2, respiratory exchange ratio (RER), heat production, 
and X ambulatory rate. X ambulatory rate is defined as the number of X-axis IR beam 
breaks every 17 minutes not including repeated interruptions of the same IR beam. No 
metabolic changes were observed in terms of VO2 (Fig 10-1), and heat production (Fig 
10-3) in chow or dextrose fed WT or KO mice. However, WT dextrose mice showed 
slight increases in VO2 at 21:00 and 23:00 compared to WT chow mice. RER is 
dependent on the source of energy consumption. Increased RER in dextrose fed mice (Fig 
10-2) is a representation of carbohydrate being used as a major fuel source. Significantly 
higher values were observed between WT dextrose and KO dextrose at the beginning of 
the dark cycle between 18:00 and 23:00. WT dextrose had significant increases in X 
ambulatory rate between 21:00 and 23:00 hours compared to WT chow and KO dextrose. 
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Figure 10-1. Averaged 24 Hour Profile of VO2 in Chow vs Dextrose cohorts (left). Data represented as Mean ± 
SEM; n = 7-8 mice/group. Statistical analysis was carried out with a two-way ANOVA with repeated measures and 
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Bonferroni's post-hoc analysis test for individual comparisons. Significance is designated by WT chow vs WT dextrose 
^P < 0.05, ^^P < 0.01. 
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Figure 10-2. Averaged 24 Hour Profile of RER in Chow vs Dextrose cohorts (left). Data represented as Mean ± 
SEM; n = 7-8 mice/group. Statistical analysis was carried out with a two-way ANOVA with repeated measures and 
Bonferroni's post-hoc analysis test for individual comparisons. Significance is designated by WT chow vs WT dextrose 
^P < 0.05; KO chow vs KO dextrose &P < 0.05, &&P < 0.01, &&&P < 0.001; WT dextrose vs KO dextrose $P < 
0.05. 
6:
00
7:
00
8:
00
9:
00
10
:0
0
11
:0
0
12
:0
0
13
:0
0
14
:0
0
15
:0
0
16
:0
0
17
:0
0
18
:0
0
19
:0
0
20
:0
0
21
:0
0
22
:0
0
23
:0
0
0:
00
1:
00
2:
00
3:
00
4:
00
5:
00
0.30
0.35
0.40
0.45
0.50
0.55
0.60 WT Chow
KO Chow
WT Dextrose
KO Dextrose
Time of  Day
H
e
a
t 
(k
c
a
l/
h
r)
 
Figure 10-3. Averaged 24 Hour Profile of Heat Production in Chow vs Dextrose cohorts (left). Data represented 
as Mean ± SEM; n = 7-8 mice/group. 
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Figure 10-4. Averaged 24 Hour Profile of X Ambulatory Rate in Chow vs Dextrose cohorts (left). Data 
represented as Mean ± SEM; n = 7-8 mice/group. Statistical analysis was carried out   with a two-way ANOVA with 
repeated measures and Bonferroni's post-hoc analysis test for individual comparisons. Significance is designated by 
WT chow vs WT dextrose ^P < 0.05, ^^P < 0.01, ^^^P < 0.001; WT dextrose vs KO dextrose $P < 0.05, $$$P < 0.001. 
 
Figure 11 shows the metabolic rate assessment of sucrose fed mice compared to chow fed 
controls. On average, WT and FGF21 KO sucrose fed mice had significantly higher VO2 
than chow fed counterparts over a 24-hour period. (Figure 11-1). Similarly, RER is 
increased because of the carbohydrate consumption by these mice (Figure 11-2). Sucrose 
fed WT mice had significant increases in heat production at the beginning and end of the 
dark cycle, or 18:00 and 3:00 respectively (Figure 11-3). WT sucrose mice showed 
significant increases in X ambulatory movement at 18:00, 19:00, 23:00, 2:00, and 3:00 
compared to WT chow mice (Figure 11-4).  
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Figure 11-1. Averaged 24 Hour Profile of VO2 in Chow vs Sucrose cohorts (left). Data represented as Mean ± 
SEM; n = 6-8 mice/group. Statistical analysis was carried out with a two-way ANOVA with repeated measures and 
Bonferroni's post-hoc analysis test for individual comparisons. Significance is designated by WT chow vs WT sucrose 
^P < 0.05, ^^P < 0.01, ^^^P < 0.001; KO chow vs KO sucrose &P < 0.05. 
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Figure 11-2. Averaged 24 Hour Profile of RER in Chow vs Sucrose cohorts (left). Data represented as Mean ± 
SEM; n = 6-8 mice/group. Statistical analysis was carried out with a two-way ANOVA with repeated measures and 
Bonferroni's post-hoc analysis test for individual comparisons. Significance is designated by WT chow vs WT sucrose 
^P < 0.05, ^^P < 0.01, ^^^P < 0.001; KO chow vs KO sucrose &&P < 0.01, &&&P < 0.001. 
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Figure 11-3. Averaged 24 Hour Profile of Heat Production in Chow vs Sucrose cohorts (left). Data represented as 
Mean ± SEM; n = 6-8 mice/group. Statistical analysis was carried out with a two-way ANOVA with repeated measures 
and Bonferroni's post-hoc analysis test for individual comparisons. Significance is designated by WT chow vs WT 
sucrose ^P < 0.05. 
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Figure 11-4. Averaged 24 Hour Profile of X Ambulatory Rate in Chow vs Sucrose cohorts (left). Data represented 
as Mean ± SEM; n = 6-8 mice/group. Statistical analysis was carried out with a two-way ANOVA with repeated 
measures and Bonferroni's post-hoc analysis test for individual comparisons. Significance is designated by WT chow vs 
WT sucrose ^P < 0.05, ^^^P < 0.001. 
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The metabolic rate assessment of fructose fed mice compared to chow fed mice is shown 
in Figure 12. Fructose fed FGF21KO mice have higher energy expenditure in terms of 
VO2 (Fig 12-1) compared to the WT fructose fed mice. No differences were observed in 
WT and KO chow fed mice in terms of VO2. These mice also had higher heat production 
(Fig 12-3). RER is shown to significantly increase at the beginning of the dark cycle due 
to the carbohydrate consumption by fructose fed mice (Figure 12-2). WT fructose mice 
showed significant increases in X ambulatory movement at 23:00 and 5:00 compared to 
WT chow mice (Figure 12-4) 
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Figure 12-1. Averaged 24 Hour Profile of VO2 in Chow vs Fructose cohorts (left). Data represented as Mean ± 
SEM; n = 7-8 mice/group. Statistical analysis was carried out with a two-way ANOVA with repeated measures and 
Bonferroni's post-hoc analysis test for individual comparisons. Significance is designated by WT chow vs KO chow *P 
< 0.05; WT fructose vs KO fructose $P < 0.05. 
 36 
6:
00
7:
00
8:
00
9:
00
10
:0
0
11
:0
0
12
:0
0
13
:0
0
14
:0
0
15
:0
0
16
:0
0
17
:0
0
18
:0
0
19
:0
0
20
:0
0
21
:0
0
22
:0
0
23
:0
0
0:
00
1:
00
2:
00
3:
00
4:
00
5:
00
0.7
0.8
0.9
1.0
1.1 WT Chow
KO Chow
WT Fructose
KO Fructose
^^^
^
^
^^
^^ ^^
^
Time of  Day
R
E
R
 
Figure 12-2. Averaged 24 Hour Profile of RER in Chow vs Fructose cohorts (left). Data represented as Mean ± 
SEM; n = 7-8 mice/group. Statistical analysis was carried out with a two-way ANOVA with repeated measures and 
Bonferroni's post-hoc analysis test for individual comparisons. Significance is designated by WT chow vs WT fructose 
^P < 0.05, ^^P < 0.01, ^^^P < 0.001. 
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Figure 12-3. Averaged 24 Hour Profile of Heat Production in Chow vs Fructose cohorts (left).  Data represented 
as Mean ± SEM; n = 7-8 mice/group. 
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Figure 12-4. Averaged 24 Hour Profile of X Ambulatory Rate in Chow vs Fructose cohorts (left). Data 
represented as Mean ± SEM; n = 7-8 mice/group. Statistical analysis was carried out with a two-way ANOVA with 
repeated measures and Bonferroni's post-hoc analysis test for individual comparisons. Significance is designated by 
WT chow vs KO chow *P < 0.05; WT chow vs WT fructose ^P < 0.05, ^^^P < 0.001. 
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DISCUSSION 
 
There is increasing concern about the potential threat to health represented by a 
high intake of sugars, as evidenced by the recent Dietary Guidelines for Americans 
(Zelber-Sagi et al., 2007), UK Scientific Advisory Committee for Nutrition’s 
Carbohydrate report (Chalasani et al., 2012) and the WHO Sugars Report (Ma et al., 
2015).There are cross-sectional surveys and also prospective cohort studies and 
controlled intervention trials supporting the possibility that increased sugar consumption 
is a contributor to the worldwide epidemics of obesity and diabetes and their associated 
cardio-metabolic risks. The increasing prevalence of obesity is paralleled by a less 
obvious epidemic, that of NAFLD. While hepatic steatosis, the first stage in NAFLD, is 
considered relatively benign with respect to liver disease per se, it may progress to non-
alcoholic steatohepatitis (NASH) and may progress further to cirrhosis or hepatocellular 
carcinoma.  
Evidence suggests that high sugar diets both directly and indirectly promote the 
development of metabolic disease. It is promoted directly by lipid and carbohydrate 
metabolism and indirectly by promoting positive energy balance which will also 
eventually cause dysregulation of lipid and carbohydrate metabolism.  
Sugar is typically consumed by humans in the form of sucrose or high fructose 
corn syrup (HFCS), both of which consist of nearly equal amounts of the simple sugars, 
glucose and fructose. Glucose is the predominant form of circulating sugar in animals, 
while sucrose, the disaccharide composed of equal portions of glucose and fructose, is the 
predominant circulating sugar in plants. The fructose component of sugar appears to be 
 39 
particularly harmful as excessive consumption of fructose, but not glucose, increases 
visceral adiposity, serum triglycerides, and insulin resistance (Stanhope et al., 2009). 
Fructose consumption also stimulates DNL more than glucose (Hudgins, Parker, Levine, 
& Hellerstein, 2011; Schwarz et al., 2015; Stanhope et al., 2009), which contributes to the 
development of steatosis and NAFLD (Donnelly et al., 2005; Lambert, Ramos-Roman, 
Browning, & Parks, 2014). The differential effects of glucose and fructose on NAFLD 
and other features of metabolic syndrome are, in part, due to the fact that fructose is 
preferentially metabolized in the liver (Stanhope, Schwarz, & Havel, 2013). Compared to 
other carbohydrates, fructose has a unique intestinal transporter (GLUT5) and inter-organ 
trafficking pathways that contributes to its efficient energy storage within the body 
(Tappy, 2018). 
Our lab has recently demonstrated that fructose, but not glucose, ingestion acutely 
and robustly increases FGF21 secretion in both human and mice (J. R. Dushay et al., 
2015; Ffolliott M. Fisher et al., 2017). After 8 weeks of high-fructose diet, livers from 
FGF21 knockout mice demonstrate atrophy and fibrosis accompanied by molecular 
markers of inflammation and stellate cell activation compared to the control mice. Role 
of FGF21 in carbohydrate metabolism in general is well recognized and with the previous 
studies we know that FGF21 plays a role in fructose metabolism.  
Fibroblast growth factor 21 (FGF21) is a metabolic hormone synthesized by 
multiple tissues and released into circulation largely by the liver (Badman et al., 2007; 
Kharitonenkov et al., 2005; Markan et al., 2014). Pharmacological administration has 
multiple beneficial metabolic effects (Kharitonenkov & DiMarchi, 2015). FGF21 was 
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initially identified as a liver hormone regulated by fasting and ketogenic diets under the 
transcriptional control of PPAR-alpha, a master regulator of fatty acid oxidation (Badman 
et al., 2007; Inagaki et al., 2007; Kharitonenkov et al., 2005; Potthoff et al., 2009). The 
liver enriched transcription factor CREBH interacts with PPAR-alpha and also 
participates in regulating FGF21 expression after fasting or high-fat, low-carbohydrate 
feeding (Kim et al., 2014; Park et al., 2016, p. 21). In humans, fructose ingestion leads to 
a robust and rapid increase in circulating levels of FGF21, which return to baseline after 
several hours. Thus FGF21's function in humans may be unrelated to fasting physiology 
(Christodoulides et al., 2009; J. Dushay et al., 2010; Gälman et al., 2008). 
The current thesis work intends to explore and compare the physiological 
responses caused by fructose, glucose, and sucrose consumption in murine models. 
Interestingly, female WT and FGF21 KO mice exposed to a refined sugar diet for 20 
weeks exhibited no significant increases in body weights compared to controls 
counterparts (Fig 2). Additionally, the total caloric consumption was similar between the 
cohorts (Fig 3). 
Interestingly, mice fed with sucrose diet had less fat mass accumulation over time 
(Fig 4). The reduction of fat mass was more pronounced in FGF21 KO mice compared to 
the WT mice on the same diet. Mice maintained similar lean mass irrespective of the diet 
or genotype. After chronic consumption of diet for 16-18 weeks, impaired glucose 
tolerance was observed in dextrose and fructose fed FGF21 KO mice compared to 
controls.  However, insulin sensitivity was only impaired in sucrose fed mice. Hepatic 
 41 
gluconeogenesis as assessed by pyruvate tolerance test was only increased in fructose fed 
KO mice.  
To assess the energy expenditure paradigm in all the cohorts, indirect calorimetry 
was performed. Dextrose alone did not increase the energy expenditure in mice, however, 
sucrose fed WT mice and FGF21 KO mice fed either with sucrose or fructose had higher 
energy expenditure compared to their counterparts. The most dramatic changes were 
observed in RER, consistent with the utilization of carbohydrates over fat for baseline 
energy expenditure, which may explain the lower weight gains observed in all cohorts. 
However, molecular gene expression of uncoupling proteins (UCPs), genetic markers of 
energy expenditure found in the inner mitochondrial membrane, and KLB is required for 
the confirmation of these results. 
Overall, we see differential effects of all these diets in the WT and FGF21 
deficient mice. Chronic consumption of dextrose only affected glucose sensitivity. 
Whereas chronic consumption of sucrose influences glucose and insulin sensitivity and 
energy expenditure suggesting internal metabolic changes. Fructose consumption 
additionally showed increased hepatic gluconeogenesis, without the marked increase in 
insulin sensitivity, but did not appear to correlate with metabolic changes. However, 
detailed tissue analysis is required to determine specific pathological, physiological and 
molecular changes between refined sugar cohorts in mice. 
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